These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29969054)

  • 21. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
    Bouton TC; de Vos M; Ragan EJ; White LF; Van Zyl L; Theron D; Horsburgh CR; Warren RM; Jacobson KR
    PLoS One; 2019; 14(10):e0223308. PubMed ID: 31622366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H; Roopadevi HS
    J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 25. Bedaquiline: Introducing a new drug to the MDR TB armamentarium.
    Kambili C
    Indian J Tuberc; 2016 Jul; 63(3):137-138. PubMed ID: 27865232
    [No Abstract]   [Full Text] [Related]  

  • 26. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 27. Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis.
    Deoghare S
    Indian J Pharmacol; 2013; 45(5):536-7. PubMed ID: 24130398
    [No Abstract]   [Full Text] [Related]  

  • 28. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
    Udwadia ZF; Amale RA; Mullerpattan JB
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid emergence of
    Veziris N; Bernard C; Guglielmetti L; Le Du D; Marigot-Outtandy D; Jaspard M; Caumes E; Lerat I; Rioux C; Yazdanpanah Y; Tiotiu A; Lemaitre N; Brossier F; Jarlier V; Robert J; Sougakoff W; Aubry A; ;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182568
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
    Andres S; Merker M; Heyckendorf J; Kalsdorf B; Rumetshofer R; Indra A; Hofmann-Thiel S; Hoffmann H; Lange C; Niemann S; Maurer FP
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1564-1568. PubMed ID: 32053752
    [No Abstract]   [Full Text] [Related]  

  • 34. A review of tuberculosis: Focus on bedaquiline.
    Chan B; Khadem TM; Brown J
    Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    ; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
    Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.
    de Vos M; Ley SD; Wiggins KB; Derendinger B; Dippenaar A; Grobbelaar M; Reuter A; Dolby T; Burns S; Schito M; Engelthaler DM; Metcalfe J; Theron G; van Rie A; Posey J; Warren R; Cox H
    N Engl J Med; 2019 May; 380(22):2178-2180. PubMed ID: 31141643
    [No Abstract]   [Full Text] [Related]  

  • 39. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.